ZIOPHARM Oncology Reports Median Overall Survival in Expanded 20 mg Cohort Maintained at 12.5 Months and Continues to Compare Favorably to Historical Controls; Impact of Steroids and Circulating Immune Cells Correlate with Immune Activation by IL-12